Liu Shuna, Wu Ming, Wang Fang
Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 210029.
National Key Clinical Department of Laboratory Medicine, Nanjing, China, 210029.
J Cancer. 2021 May 13;12(13):3976-3996. doi: 10.7150/jca.47695. eCollection 2021.
Ovarian cancer is a serious threat to women's health; its early diagnosis rate is low and prone to metastasis and recurrence. The current conventional treatment for ovarian cancer is a combination of platinum and paclitaxel chemotherapy based on surgery. The recurrence and progression of ovarian cancer with poor prognosis is a major challenge in treatment. With rapid advances in technology, understanding of the molecular pathways involved in ovarian cancer recurrence and progression has increased, biomarker-guided treatment options can greatly improve the prognosis of patients. This review systematically discusses and summarizes existing and new information on prognostic factors and biomarkers of ovarian cancer, which is expected to improve the clinical management of patients and lead to effective personalized treatment.
卵巢癌是对女性健康的严重威胁;其早期诊断率低,且易于转移和复发。目前卵巢癌的传统治疗方法是以手术为基础,联合铂类和紫杉醇化疗。预后较差的卵巢癌复发和进展是治疗中的一项重大挑战。随着技术的飞速发展,对卵巢癌复发和进展所涉及分子途径的认识有所增加,生物标志物引导的治疗方案能够极大地改善患者的预后。本综述系统地讨论并总结了有关卵巢癌预后因素和生物标志物的现有及新信息,有望改善患者的临床管理并实现有效的个性化治疗。